1. |
Rijal H, Bouadi N, Bourkas AN, Geng R,
Molin S. Outcomes of JAK Inhibitor Therapy in Pyoderma
Gangrenosum: A Systematic Review. J Cutan Med Surg 2024 Aug
28:12034754241277503. |
2. |
Scheinberg M, Machado LA, M Castro LG,
Ferreira SB, Michalany N. Successful treatment of ulcerated
pyoderma gangrenosum with baricitinib, a novel JAK inhibitor. J
Transl Autoimmun 2021;4:100099. |
3. |
Marquès-Camí M,
García-Guiñón A, Garreta J, Voltà T, Torres G, Sesé E. A
61-year-old patient with Crohn's disease and severe
postoperative recurrence responding to JAK inhibitor ruxolitinib
for polycythemia vera treatment. Gastroenterol Hepatol 2022;45
Suppl 1:16-17. |
4. |
Grisé A, Valere LC, Weinstein D, Sami N.
Janus kinase inhibitors in the treatment of pyoderma
gangrenosum: case report and review. Arch Dermatol Res
2024;316(6):238. |
5. |
Yamanaka K. New treatment of pyoderma
gangrenosum and hidradenitis suppurativa: A review. J Dermatol
2024;51(2):172-179. |
6. |
Jensen LT, Attfield KE, Feldmann M,
Fugger L. Allosteric TYK2 inhibition: redefining autoimmune
disease therapy beyond JAK1-3 inhibitors. EBioMedicine
2023;97:104840. |
7. |
Blair HA. Ritlecitinib: First Approval.
Drugs 2023;83(14):1315-1321. Liu M, Gao Y, Yuan Y, Yang K, Shen
C, Wang J, Tian J. Janus Kinase Inhibitors for Alopecia Areata:
A Systematic Review and Meta-Analysis. JAMA Netw Open
2023;6(6):e2320351. |
8. |
Ibrahim O, Bayart CB, Hogan S, Piliang M,
Bergfeld WF. Treatment of Alopecia Areata With Tofacitinib. JAMA
Dermatol 2017;153(6):600-602. |
9. |
He X, Yang D, Lai L, Lang J, Wei K, Xiao
M. Upadacitinib for Alopecia Areata in Different Backgrounds: A
Case Series. Clin Cosmet Investig Dermatol 2024;17:565-571. |
10. |
Edwards SJ, Karner C, Jhita T, Barton S,
Marceniuk G, Yiu ZZN, Wittmann M. Abrocitinib, tralokinumab and
upadacitinib for treating moderate-to-severe atopic dermatitis.
Health Technol Assess 2024;28(4):1-113. |
11. |
Bennett M, Moussa A, Sinclair R.
Successful treatment of chronic severe alopecia areata with
abrocitinib. Australas J Dermatol 2022;63(2):274-276. |
12. |
King B, Guttman-Yassky E, Peeva E,
Banerjee A, Zhu L, Zhu H, Cox LA, Vincent MS, Sinclair R. Safety
and Efficacy of Ritlecitinib and Brepocitinib in Alopecia
Areata: Results from the Crossover Open-Label Extension of the
ALLEGRO Phase 2a Trial. JID Innov 2022;2(6):100156. |
13. |
Mackay-Wiggan J, Jabbari A, Nguyen N,
Cerise JE, Clark C, Ulerio G, Furniss M, Vaughan R, Christiano
AM, Clynes R. Oral ruxolitinib induces hair regrowth in patients
with moderate-to-severe alopecia areata. JCI Insight
2016;1(15):e89790. |
14. |
Berbert Ferreira S, Berbert Ferreira R,
Scheinberg MA. Atopic dermatitis: Tofacitinib, an option for
refractory disease. Clin Case Rep 2020;8(12):3244-3247. |
15. |
Ezzedine K, Peeva E, Yamaguchi Y, Cox LA,
Banerjee A, Han G, Hamzavi I, Ganesan AK, Picardo M, Thaçi D,
Harris JE, Bae JM, Tsukamoto K, Sinclair R, Pandya AG, Sloan A,
Yu D, Gandhi K, Vincent MS, King B. Efficacy and safety of oral
ritlecitinib for the treatment of active nonsegmental vitiligo:
A randomized phase 2b clinical trial. J Am Acad Dermatol
2023;88(2):395-403. |
16. |
Miot HA, Criado PR, de Castro CCS, Ianhez
M, Talhari C, Ramos PM. JAK-STAT pathway inhibitors in
dermatology. An Bras Dermatol 2023;98(5):656-677. |
17. |
Van Buchem-Post NF, Wolkerstorfer A,
Bekkenk MW. Vitiligo: JAK, de nieuwe aanpak. Nederlands
Tijdschrift voor Dermatologie en Venereologie 2024;34(5):53-55. |
18. |
Inoue S, Suzuki T, Sano S, Katayama
I. JAK inhibitors for the treatment of vitiligo. J Dermatol Sci
2024;113(3):86-92. |
19. |
Martora F, Scalvenzi M, Ruggiero A,
Potestio L, Battista T, Megna M. Hidradenitis Suppurativa and
JAK Inhibitors: A Review of the Published Literature. Medicina
(Kaunas) 2023;59(4):801. |
20. |
Kirby JS, Okun MM, Alavi A, Bechara FG,
Zouboulis CC, Brown K, Santos LL, Wang A, Bibeau KB, Kimball AB,
Porter ML. Efficacy and safety of the oral Janus kinase 1
inhibitor povorcitinib (INCB054707) in patients with
hidradenitis suppurativa in a phase 2, randomized, double-blind,
dose-ranging, placebo-controlled study. J Am Acad Dermatol
2024;90(3):521-529. |
21. |
Heidari A, Ghane Y, Heidari N, Sadeghi S,
Goodarzi A. A systematic review of Janus kinase inhibitors and
spleen tyrosine kinase inhibitors for Hidradenitis suppurativa
treatment. Int Immunopharmacol 2024;127:111435. |
22. |
Kimball AB, Peeva E, Forman S, Moiin A,
Khattri S, Porter ML, Mangold AR, Ghosh P, Banfield C, Oemar B.
Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis
Suppurativa. NEJM Evid 2024;3(3):EVIDoa2300155. |
23. | Honap S, Agorogianni A, Colwill MJ, Mehta
SK, Donovan F, Pollok R, Poullis A, Patel K. JAK inhibitors for
inflammatory bowel disease: recent advances. Frontline
Gastroenterol 2023;15(1):59-69. |
24. |
Rudra S, Shaul E, Conrad M, Patel T,
Moore A, Dawany N, Canavan MC, Sullivan KE, Behrens E, Kelsen
JR. Ruxolitinib: Targeted Approach for Treatment of
Autoinflammatory Very Early Onset Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol 2022;20(6):1408-1410. |
25. |
Sandborn WJ, Danese S, Leszczyszyn J,
Romatowski J, Altintas E, Peeva E, Hassan-Zahraee M, Vincent MS,
Reddy PS, Banfield C, Salganik M, Banerjee A, Gale JD, Hung KE.
Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe
Ulcerative Colitis: Results From a Randomized, Phase 2b Study.
Clin Gastroenterol Hepatol 2023;21(10):2616-2628.e7. |
26. |
Fagan N, Doherty GA, Meah N, Sinclair R,
Wall D. Cross-specialty identification of the JAK1 inhibitor
trial agent filgotinib as a potential therapy for alopecia
areata. Br J Dermatol 2023;188(3):442-443. |
27. |
Kang Y, Jiang X, Qin D, Wang L, Yang J,
Wu A, Huang F, Ye Y, Wu J. Efficacy and Safety of Multiple
Dosages of Fostamatinib in Adult Patients With Rheumatoid
Arthritis: A Systematic Review and Meta-Analysis. Front
Pharmacol 2019;10:897. |
28. |
Robinson MF, Damjanov N, Stamenkovic B,
Radunovic G, Kivitz A, Cox L, Manukyan Z, Banfield C, Saunders
M, Chandra D, Vincent MS, Mancuso J, Peeva E, Beebe JS. Efficacy
and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC
Inhibitor, in Patients With Moderate-to-Severe Rheumatoid
Arthritis and an Inadequate Response to Methotrexate. Arthritis
Rheumatol 2020;72(10):1621-1631. |
29. |
Caporali R, Taylor PC, Aletaha D,
Sanmartí R, Takeuchi T, Mo D, Haladyj E, Bello N,
Zaremba-Pechmann L, Fang Y, Dougados M. Efficacy of baricitinib
in patients with moderate-to-severe rheumatoid arthritis up to
6.5 years of treatment: results of a long-term study.
Rheumatology (Oxford) 2024;63(10):2799-2809. |
30. |
Mease P, Coates LC, Helliwell PS, Stanislavchuk M, Rychlewska-Hanczewska A, Dudek A, Abi-Saab W, Tasset C, Meuleners L, Harrison P, Besuyen R, Van der Aa A, Mozaffarian N, Greer JM, Kunder R, Van den Bosch F, Gladman DD. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet 2018;392(10162):2367-2377. |